← All trials
NCT04971161
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2021
- Primary completion
- Aug 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- Jul 21, 2021
- Last posted
- Nov 17, 2021
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rheacell GmbH & Co. KGLead sponsor
- FGK Clinical Research GmbHCollaborator
- TICEBA GmbHCollaborator
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg, GermanyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.